Fortrea Holdings FTRE
NASDAQ FTRE
$18.27 -0.35 (-1.85%)
As of: Sep 4, 2026 · 11:50 AM EDT

Fortrea Holdings (FTRE) Profit After Tax (2022 - 2026)

Fortrea Holdings' (FTRE) quarterly Profit After Tax came in at -$13.2 million in Q2 2026, up 96.48% YoY from -$6.7 million in Q2 2025, and up 48.03% on a QoQ basis from -$25.4 million in Q1 2026.

Analysis

Fortrea Holdings (FTRE) Profit After Tax (2022 - 2026) Analysis & Trends

Fortrea Holdings (FTRE) has 5 years of Profit After Tax data on file, last reported at -$13.2 million in Q2 2026.

  • Quarterly Profit After Tax rose 96.48% year-over-year to -$13.2 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was -$87.0 million (up 91.53% YoY) and the FY2025 annual result came in at -$986.2 million, down 200.21% from the prior year.
  • Profit After Tax improved to -$13.2 million in Q2 2026, from -$25.4 million in the prior quarter.
  • In the past five years, Profit After Tax ranged from a high of $60.6 million in Q3 2022 to a low of -$562.9 million in Q1 2025.
  • A 5-year average of -$81.0 million and a median of -$27.9 million in 2024 frame the typical range for Profit After Tax.
  • Annual changes were most pronounced in 2023 — Profit After Tax soared 137.38% — and 2024, when it tumbled 628.8%.
  • Tracing FTRE's Profit After Tax over 5 years: stood at $26.7 million in 2022, then plunged by 328.46% to -$61.0 million in 2023, then decreased by 0.33% to -$61.2 million in 2024, then surged by 46.9% to -$32.5 million in 2025, then surged by 59.38% to -$13.2 million in 2026.
  • The last three Profit After Tax figures came in at -$13.2 million (Q2 2026), -$25.4 million (Q1 2026), and -$32.5 million (Q4 2025), per Business Quant data.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) PAT (Qtr)
1 Vertex Pharmaceuticals 140.22 Bn 132.37 Bn 2.84 Bn 1.10 Bn
2 Regeneron Pharmaceuticals 86.04 Bn 78.05 Bn 3.93 Bn 1.30 Bn
3 Argenx Se 63.70 Bn 58.52 Bn 1.37 Bn 472.00 Mn
4 Moderna 57.56 Bn 52.42 Bn 52.00 Mn -782.00 Mn
5 Revolution Medicines 44.05 Bn 44.05 Bn - -644.37 Mn
6 BeOne Medicines 40.16 Bn 35.06 Bn 1.53 Bn 237.01 Mn
7 Alnylam Pharmaceuticals 35.63 Bn 32.32 Bn 992.69 Mn 164.49 Mn
8 Royalty Pharma 28.63 Bn 27.79 Bn - 81.49 Mn
9 Insmed 27.73 Bn 26.57 Bn 358.27 Mn -16.62 Mn
10 Fortrea Holdings 1.73 Bn 1.56 Bn 139.20 Mn -13.20 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -13.20 Mn
Mar 31, 2026 -25.40 Mn
Dec 31, 2025 -32.50 Mn
Sep 30, 2025 -15.90 Mn
Jun 30, 2025 -374.90 Mn
Mar 31, 2025 -562.90 Mn
Dec 31, 2024 -61.20 Mn
Sep 30, 2024 -27.90 Mn
Jun 30, 2024 -138.40 Mn
Mar 31, 2024 -101.00 Mn
Dec 31, 2023 -61.00 Mn
Sep 30, 2023 -16.10 Mn
Jun 30, 2023 32.00 Mn
Mar 31, 2023 19.10 Mn
Dec 31, 2022 26.70 Mn
Sep 30, 2022 60.60 Mn
Jun 30, 2022 -85.60 Mn